Gloria E. Meredith, BS, MS, PhD was appointed Dean and CAO on July 1, 2009. For the past 26 years, Dean Meredith has held academic appointments at four Medical Schools and Universities and has been active in biomedical research and the clinical education of students, fellows and residents. She has had 10 years experience in administration, including serving as the Chair of the Pharmacology Department in the Medical School, 26 years in Biomedical Research, 29 years in Medical and Healthcare Education, including seven years in Interprofessional Education (she also served on the committee that founded Interprofessional Education in the University). Previously, she was Associate Professor in the Department of Basic Medical Science at the University of Missouri-Kansas City (UMKC) School of Medicine and Adjunct Associate Professor in the UMKC Pharmacy School. While in Kansas City and working with faculty and pharmacy students, she initiated an extensive research program in Parkinson‘s Disease. Prior to moving to Kansas City, Dr Meredith was an Associate Professor at the Royal College of Surgeons in Ireland, after working as an Assistant Professor at the Free University of Amsterdam. Dean Meredith has extensive experience in education - in course design and development, Problem-Based Learning, small group (clinical case) learning, as well as more formal lecturing – and has been extensively involved in the professional education of surgeons, nurses and medical residents, receiving the top teaching award of the College of Surgeons in 1996. In her research, Dean Meredith is a classical neuropharmacologist who has been continuously funded since 1994, including NIH funding since 2001. She now focuses on studies of neuroprotection and levodopa-induced dyskinesia in Parkinson‘s disease, and on basic mechanisms of drug craving in an animal model of amphetamine abuse. She has published more than 160 publications in top quality journals, including, co-authoring in 2007 an article in Nature that tested a potential neuroprotective drug for Parkinson‘s disease that has just completed Phase II clinical trials. She has served on NIH study sections and is affiliated with many professional societies such as Sigma Xi (Honor Society), AACP, American Society of Health System Pharmacists, North Suburban Pharmacists of Chicagoland Association, and Pharmacy Society of Wisconsin. She serves as an officer in the local chapter of the American Society of Pharmacology and Experimental Therapeutics, has been a past officer in the American Society of Medical School Pharmacology Chairs, and serves on a Deans' Task Force for AACP. She has played a role in the recent accreditation review of RFUMS by the HLC, and chaired the committee to develop the COP.